Kejadian Mielosupresi Pada Penderita Kanker Kepala Dan Leher Yang Mendapat Kemoterapi Cisplatin Dan Carboplatin Di RSUP Dr. Kariadi Semarang
DOI:
https://doi.org/10.36408/mhjcm.v7i1.425Keywords:
Kemoterapi Cisplatin/Carboplatin, kanker kepala dan leher, mielosupresiAbstract
Latar belakang : Kemoterapi bersifat sistemik dan non selektif sehingga tidak hanya sel kanker yang mati tetapi juga sel normal. National Comprehensive Cancer Network (NCCN) merekomendasikan Platinum-based sebagai rejimen kemoterapi untuk kanker kepala dan leher terutama Cisplatin dan Carboplatin. Cisplatin dan Carboplatin dapat menyebabkan efek samping mielosupresi.
Tujuan : Membuktikan bahwa terdapat perbedaan kejadian mielosupresi pada penderita Kanker Kepala dan Leher (KKL) yang mendapat kemoterapi Cisplatin dan Carboplatin.
Metode : Penelitian observasional dengan desain penelitian kohort prospektif di klinik THT-KL, bangsal dan bagian rekam medis instalasi rawat jalan/rawat inap RSUP Dr. Kariadi Semarang. Sampel ditentukan sebanyak 90 orang dan mendapat kemoterapi platinum based dengan salah satu komponen berupa Cisplatin atau Carboplatin sebanyak 3 seri. Analisis data dengan uji Pearson Chi-square dan Fisher’s exact test.
Hasil : Subyek penelitian 90 orang, 45 orang mendapatkan Paclitaxel Cisplatin dan 45 orang mendapatkan regimen Paclitaxel Carboplatin. Hasil penelitian ini didapatkan 48,9% pasien stadium IV, histopatologi terbanyak WHO 3 (83,3%). Rerata usia terbanyak 50-59 tahun, dan diagnosis terbanyak pada KNF (66,7%). Secara keseluruhan kemoterapi seri I menunjukkan Carboplatin menyebabkan perubahan kadar hemoglobin (p=1,000) dan leukosit (p=0,292) dengan jumlah subyek lebih banyak dibanding Cisplatin. Sedangkan pada kemoterapi seri III, Carboplatin menyebabkan perubahan kadar hemoglobin (p=<0,023), leukosit (p=0,670), dan trombosit (p=1,000) lebih banyak dibandingkan Cisplatin.
Simpulan : Kadar hemoglobin berbeda bermakna pada pasien yang mendapatkan kemoterapi Carboplatin seri III (p<0,023).
Kata kunci : Kemoterapi Cisplatin/Carboplatin., kanker kepala dan leher, mielosupresi.
Background : Chemotherapy is systemic and non-selective so it often results in not only cancer cells dying but normal cells will also die. The National Comprehensive Cancer Network (NCCN) recommends Platinum-based chemotherapy regimens for head and neck cancer, especially Cisplatin and Carboplatin. Cisplatin and Carboplatin chemotherapy can cause one of the side effects of myelosuppression. Myelosuppression is a decrease in cell production of leukocytes, erythrocytes, and / or platelets.
Objective : Proving the difference incidence of myelosuppression in head and neck cancer patients receiving Cisplatin and Carboplatin chemotherapy.
Methode : An observational study with a prospective cohort study design in ENT clinic, ward and medical record department of outpatient installation Dr. Kariadi Semarang. Samples was determined by 90 people and received platinum based chemotherapy with one component in the form of Cisplatin or Carboplatin in 3 series. Data analysis by Pearson Chi-square and Fisher’s exact test.
Result : The study subjects were 90 people, 45 people received Paclitaxel Cisplatin regimen and 45 people received Paclitaxel Carboplatin regimen. The results of this study found 48.9% of patients in stage IV conditions with the most histopathological types were WHO 3 (83.3%). Overall series I chemotherapy shows Carboplatin causes changes in hemoglobin (p=1,000) and leukocyte (p=0,292) levels with a greater number of subjects than Cisplatin. Where as in series III chemotherapy, Carboplatin causes more changes in hemoglobin (p=<0,023), leukocyte (p=0,670) and platelet (p=1,000) levels than Cisplatin.
Conclusions : Hemoglobin level was significantly different in patients who received Carboplatin series III chemotherapy (p<0,023).
Keywords : Chemotherapy, head and neck cancer, myelosuppression, Cisplatin, Carboplatin.
Downloads
References
2. Mateos JF, et al. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. Oral oncology. 2016;Vol. 63:38–43.
3. Franzmann ELS, Huang, D, Thomas, G. Head and Neck Cancer: Changing Epidemiology and Public Health Implications. Review Article Head & Neck Cancer, Oncology Journal 2010.
4. Ramdhani, Aryo. Karakteristik pasien keganasan kepala dan leher yang mendapatkan kemoterapi di RSUP Dr. Kariadi Semarang periode Maret-April 2015. [Artikel penelitian belum dipublikasi] In press 2015.
5. To'bungan N, Aliyah SH, Wijayanti N, Fachiroh J. Epidemiologi, Stadium, dan Derajat Diferensiasi Kanker Kepala dan Leher. Biogenesis Jurnal Ilmiah Biologi. 2015;Vol 3:47-52.
6. Munir M. Keganasan dibidang telinga hidung tenggorok. In: Soepardi EA IN, Bashiruddin J, Restuti RD, editor. Buku ajar ilmu kesehatan telinga, hidung, tenggorok dan kepala leher. 5 ed. Jakarta: Balai Penerbit FKUI; 2001. p. 132 -8.
7. Miller RP, Tadagavadi RK, Ramesh, G, Reevas, WB. Mechanism of cisplatin nephrotoxicity. Toxins. 2010;Vol 2:2490-518.
8. Vokes EE, Chong N. Chemotherapy of head and neck cancer. In: Perry MC, editor. The chemotherapy source book. philadelpia: Lippincot Williams & Wilkins; 2008. p. 324-38.
9. Price SA. Patofisiologi : konsep klinis proses-proses penyakit. 6 ed. Jakarta: EGC; 2006. p. 256-70.
10. Baron RE,Julve JV, Jaime SP, Santalo NB, Millan CV and Mata ML. Hemoglobin Levels and Acute Radiotherapy Induced Toxicity. Tumori 2005;Vol. 91(1):40-5.
11. Santoso S, Antono D, Yusmawan W. Pengaruh nigella sativa terhadap hemopoetik dan fungsi ginjal penderita keganasan kepala dan leher yang mendapatkan kemoterapi, Semarang: Universitas Diponegoro; 2014.
12. Mccarthy C, Field JK, Rajlawat BP, Field A, Marcus M. Trends and regional variation in the incidence of head and neck cancers in england: 2002 to 2011. International journal of oncology. 2015;47:p.204-210.
13. Tangjaturonrasme N, Vatanasapt P, Bychkov A. Epidemiology of head and neck cancer in Thailand. Asia Pac J Clin Oncol. 2018;14:p.16–22.
14. Loh JM, Tran AL, Ji L, Groshen S, Daneshmand S, Shuckman A, et al. Baseline glomerular filtration rate and cisplatin induced renal toxicity in urothelial cancer patients. Clinical Genitourinary Cancer. 2017;p.90-8.
15. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and synptoms at presentation. Chinese J cancer Association. 2012;31:p.185-95.
16. Faiza S, Rahman S, Asri A. Karakteristik klinis dan patologis karsinoma nasofaring bagian THT-KL RSUP Dr. M Djamil Padang. Jurnal Kesehatan Andalas. 2016;5(1). p. 91-96.
17. Piasiska H. Profil penderita karsinoma nasofaring di laboratorium patologi anatomi kota Medan tahun 2009 (tesis). Medan: Fakultas Kedokteran Universitas Sumatera Utara; 2010.
18. Dygai Am et al. Mechanisms of Regulation of Hemopoiesis During Experimental Cytostatic Myelosuppression Induced by Carboplatin. Bulletin of Experimental Biology and Medicine, General Pathology, and Pathophysiology. 2007; Vol.143(5): 581-4.
19. Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Franks CR. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol 1989;28(1):57-60.
20. Brockstein BE, Vokes EE. Principles of chemotherapy inthe management of head and neck cancer. In: Bailey BJ CK, editor. Head and neck surgery - otolaryngology 4ed. Philadelphia: Lippincot-William & Wilkins; 2006. p. 1428 - 41.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2020 Medica Hospitalia : Journal of Clinical Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
